Grimes & Company Inc. Takes Position in Hologic, Inc. $HOLX

Grimes & Company Inc. purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,181 shares of the medical equipment provider’s stock, valued at approximately $207,000.

Other institutional investors have also recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its position in shares of Hologic by 22.3% during the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider’s stock valued at $113,000 after buying an additional 335 shares during the last quarter. United Services Automobile Association purchased a new position in shares of Hologic during the 1st quarter valued at $347,000. SG Americas Securities LLC lifted its position in shares of Hologic by 116.6% during the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider’s stock valued at $594,000 after buying an additional 5,172 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Hologic during the 1st quarter valued at $641,000. Finally, Cambridge Investment Research Advisors Inc. lifted its position in shares of Hologic by 1.7% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider’s stock valued at $1,980,000 after buying an additional 528 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $67.73 on Wednesday. The business’s 50-day moving average price is $67.03 and its two-hundred day moving average price is $63.18. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The stock has a market cap of $15.06 billion, a P/E ratio of 28.10, a PEG ratio of 2.31 and a beta of 0.63. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter last year, the firm posted $1.06 EPS. The company’s revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HOLX. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Stephens reiterated an “overweight” rating and set a $78.00 price objective on shares of Hologic in a research note on Thursday, September 18th. Argus boosted their price objective on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Royal Bank Of Canada upgraded Hologic from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Finally, UBS Group boosted their price objective on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $80.15.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.88% of the stock is currently owned by insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.